FDA lifts partial clinical hold on Innate's cancer drug after patient death linked to disease progression
The FDA has lifted a partial clinical hold on Innate Pharma’s IND for its potential cancer drug lacutamab after it first imposed the hold in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
